STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRC
  4. [6-K] SciSparc Ltd. Current Report (Foreign Issuer)

SciSparc (SPRC) adds MDMA-PEA PTSD patent with Clearmind

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

SciSparc Ltd. (SPRC), through its subsidiary NeuroThera Labs Inc., reports progress in its collaboration with Clearmind Medicine Inc. via U.S. publication of a patent application covering a combination of MDMA and N-acylethanolamines (including PEA) for potential treatment of PTSD, anxiety and eating disorders. This expands a joint intellectual property portfolio that now includes thirteen published patent applications generated globally through the NeuroThera–Clearmind collaboration. The newly published application describes potential effects of PEA on MDMA’s therapeutic potency, dosing, side effects and therapeutic window, and is framed against the backdrop of the FDA’s July 14, 2026 final guidance on clinical development of psychedelic drugs, which explicitly includes MDMA. SciSparc also highlights its broader clinical-stage cannabinoid-based programs, including SCI-110 and SCI-210, and notes customary forward-looking statement risks.

Positive

  • None.

Negative

  • None.
Date of FDA psychedelic guidance finalization July 14, 2026 FDA finalized guidance "Psychedelic Drugs: Considerations for Clinical Investigations" explicitly including MDMA
Number of published patent applications in collaboration 13 published patent applications Joint NeuroThera-Clearmind IP portfolio generated globally through the collaboration
Filing month and report number August 2026, Report No. 4 Period covered by the Form 6-K for SciSparc Ltd.
Press release date August 24, 2026 Date SciSparc announced the MDMA-N-acylethanolamines patent application publication
N-acylethanolamines medical
"a novel combination of 3,4-methylenedioxymethamphetamine ("MDMA") and N-acylethanolamines, such as palmitoylethanolamide"
N-acylethanolamines are a family of naturally occurring fatty molecules that act as small chemical messengers inside the body, helping cells communicate about inflammation, appetite, pain and other processes. Investors care because these molecules can be targets or biomarkers for drugs, diagnostics and wellness products — like a visible readout on a dashboard that indicates whether a treatment is working or a condition is present — which affects clinical development, regulatory approval and market potential.
palmitoylethanolamide medical
"3,4-methylenedioxymethamphetamine ("MDMA") and N-acylethanolamines, such as palmitoylethanolamide ("PEA")"
Palmitoylethanolamide (PEA) is a naturally occurring fatty molecule produced in the body and sold as a supplement or experimental therapy for reducing pain and inflammation; think of it as a built‑in calming signal that helps quiet irritated tissues. Investors watch PEA because its potential medical benefits, regulatory path (supplement vs. drug), and clinical evidence drive market demand, pricing and the risk/reward of companies developing or selling PEA-based products — similar to how a promising ingredient can change the fortunes of a consumer brand.
therapeutic window medical
"potential effects on MDMA’s therapeutic potency, required dosing, associated side effects and therapeutic window"
The "therapeutic window" is the optimal range of a medication's dosage where it effectively treats a condition without causing harmful side effects. For investors, understanding this concept highlights the importance of balance—just as too little medication may be ineffective and too much can be dangerous, financial strategies or investments need to be carefully managed within safe limits to achieve desired results without undue risk.
entactogens medical
"includes classic psychedelics as well as "entactogens or empathogens such as 3,4-methylenedioxymethamphetamine (MDMA)""
A class of psychoactive drugs that reliably produce increased empathy, emotional openness and reduced social anxiety, often described as enhancing emotional connection without strong hallucinations. They matter to investors because these molecules are the focus of drug-development programs, clinical trials, and regulatory review for mental health treatments, and their legal status and trial outcomes can affect company valuations much like any medical therapy pipeline.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the "safe harbor" provisions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What key development did SciSparc Ltd. (SPRC) announce in this 6-K?
SciSparc announced U.S. publication of a patent application covering a combination of MDMA and N-acylethanolamines, including PEA, for potential treatment of PTSD, anxiety and eating disorders, advancing the joint NeuroThera–Clearmind intellectual property portfolio.

How many patent applications exist in the NeuroThera-Clearmind collaboration for SPRC?
The collaboration between NeuroThera and Clearmind has generated a joint intellectual property portfolio that includes thirteen published patent applications globally, including the newly published U.S. application for MDMA-PEA combinations.

What is the therapeutic focus of SciSparc’s new MDMA-PEA patent application for SPRC?
The newly published U.S. patent application covers the use of MDMA combined with N-acylethanolamines, such as PEA, for methods of treating post-traumatic stress disorder (PTSD), anxiety and eating disorders, and discusses potential impacts on dosing, side effects and therapeutic window.

How does recent FDA guidance relate to SciSparc’s MDMA-PEA program for SPRC?
On July 14, 2026, the FDA finalized guidance on psychedelic drug development that explicitly includes MDMA. SciSparc notes this guidance provides regulatory context for its MDMA-PEA intellectual property and addresses clinical trial design, safety and new drug application considerations.

What other drug development programs does SciSparc Ltd. (SPRC) highlight?
SciSparc highlights cannabinoid-based programs, including SCI-110 for Tourette syndrome and for Alzheimer’s disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus, as part of its broader clinical-stage portfolio.

Does SciSparc (SPRC) generate any commercial activity outside drug development?
Yes. SciSparc, through NeuroThera, owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace, in addition to its clinical-stage pharmaceutical developments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of August 2026 (Report No. 4)

 

Commission File Number: 001-38041

 

SCISPARC LTD.

(Translation of registrant’s name into English)

 

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

On August 24, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (the “Report”) and is incorporated by reference herein.

 

This Report is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release issued by SciSparc Ltd. titled “SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation.”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SCISPARC LTD.
     
  By: /s/ Oz Adler
  Name: Oz Adler
  Title: Chief Executive Officer and Chief Financial Officer

 

Date: August 24, 2026

 

3

Exhibit 99.1

 

 

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

 

U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA

 

TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its  subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has advanced with the publication in the United States of a patent application covering a novel combination of 3,4-methylenedioxymethamphetamine (“MDMA”) and N-acylethanolamines, such as palmitoylethanolamide (“PEA”), for use in methods of treating post-traumatic stress disorder (PTSD), anxiety, and eating disorders. The U.S. patent application was published by the United States Patent and Trademark Office.

 

The publication marks a significant intellectual property milestone resulting from the ongoing collaboration between NeuroThera and Clearmind. Through this collaboration, NeuroThera’s PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs, contributing to a joint intellectual property portfolio that includes thirteen published patent applications generated through the NeuroThera-Clearmind collaboration globally.

 

The newly published application includes embodiments relating to the potential use of PEA in combination with MDMA, including potential effects on MDMA’s therapeutic potency, required dosing, associated side effects and therapeutic window.

 

FDA Finalizes Guidance Addressing Psychedelic Drug Development, Including MDMA

 

The U.S. patent application publication comes at a time of increasing federal attention to the development of psychedelic medicines and recent U.S. Food and Drug Administration (“FDA”) guidance addressing the clinical development of psychedelic drugs, including MDMA.

 

On July 14, 2026, the FDA finalized its guidance, “Psychedelic Drugs: Considerations for Clinical Investigations”. The guidance provides considerations for sponsors developing psychedelic drugs for medical conditions, including psychiatric disorders and substance use disorders.

 

The FDA’s final guidance explicitly includes MDMA within its definition of psychedelic drugs, describing the category as including classic psychedelics as well as “entactogens or empathogens such as 3,4-methylenedioxymethamphetamine (MDMA).” The guidance addresses considerations relating to clinical trial design, conduct, data collection, subject safety and new drug application requirements.

 

The FDA also notes that psychedelic drugs can present unique challenges in clinical development due to their psychoactive effects and alterations in mood, cognition and perception. The guidance provides sponsors with the FDA’s current recommendations for addressing these considerations as part of psychedelic drug development.

 

For NeuroThera and Clearmind, the FDA’s explicit inclusion of MDMA in its guidance regarding psychedelic drug development provides regulatory context for the collaboration’s MDMA-PEA intellectual property.

 

 

 

 

About SciSparc Ltd. (Nasdaq: SPRC):

 

The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

 

About NeuroThera Labs Inc.

 

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

 

Forward-Looking Statements:

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential therapeutic benefits, safety, efficacy, advantages and commercial potential of the combination of MDMA and N-acylethanolamines, including PEA; the potential of PEA to enhance MDMA’s therapeutic effects, reduce dosing requirements, mitigate side effects and broaden MDMA’s therapeutic window; the potential application of such combination in the treatment of PTSD, anxiety and eating disorders; the development, scope, value and potential benefits of NeuroThera’s intellectual property portfolio and its collaboration with Clearmind; and the potential impact of the FDA’s final guidance on the development and regulatory pathway of MDMA-based therapies. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

 

Investor Contact:

 

IR@scisparc.com

Tel: +972-3-6167055

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases